Investigation of associations between blood pembrolizumab level and clinical factors for immune-related adverse events in Japanese patients with urological cancers
Not Applicable
Recruiting
- Conditions
- urological cancers, including renal cell cancer, urothelial cancer, and bladder cancer
- Registration Number
- JPRN-UMIN000043914
- Lead Sponsor
- Department of Hospital pharmacy, Hamamatsu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who are judged by physicians as inappropriate for study enrollment
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method